This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, A. W.
Right arrow Articles by Stein, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, A. W.
Right arrow Articles by Stein, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1974-1976, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Direct Measurement of the Anti-Influenza Agent Zanamivir in the Respiratory Tract following Inhalation

Amy W. Peng,1,* Stefano Milleri,2 and Daniel S. Stein1

Clinical Pharmacology Department, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709,1 and Glaxo Wellcome S.p.A., Medicine Research Centre, Verona, Italy2

Received 7 October 1999/Returned for modification 23 January 2000/Accepted 5 April 2000

In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.

* Corresponding author. Mailing address: Clinical Pharmacology Department, Glaxo Wellcome Inc., 5 Moore Dr., Research Triangle Park, NC 27709. Phone: (919) 483-5445. Fax: (919) 483-6380. E-mail: ap4872{at}glaxowellcome.com.

Antimicrobial Agents and Chemotherapy, July 2000, p. 1974-1976, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Koyama, K., Takahashi, M., Oitate, M., Nakai, N., Takakusa, H., Miura, S.-i., Okazaki, O. (2009). CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract. Antimicrob. Agents Chemother. 53: 4845-4851 [Abstract] [Full Text]  
  • Hurt, A. C., Holien, J. K., Barr, I. G. (2009). In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses. Antimicrob. Agents Chemother. 53: 4433-4440 [Abstract] [Full Text]  
  • Wong, S. S. Y., Yuen, K.-y. (2006). Avian Influenza Virus Infections in Humans. Chest 129: 156-168 [Abstract] [Full Text]  
  • Snell, N. J. C. (2001). New treatments for viral respiratory tract infections--opportunities and problems. J Antimicrob Chemother 47: 251-259 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»